News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ariana Pharma Expands Operations to USA, Appoints James M. Shanahan VP Business Development of Subsidiary "Ariana Data Intelligence, Inc."



5/31/2012 10:49:23 AM

Cambridge, Massachusetts, USA and Paris, France, May 31, 2012 - Ariana Pharma, a provider of “non-statistical” clinical data analysis technology to the pharmaceutical industry including the FDA, announces today that it has expanded its global operations by establishing a permanent US office in Cambridge, Massachusetts to service growing demand for its unique and powerful data analytics technology KEM(R).

In conjunction with the opening, Ariana has appointed James M. Shanahan as VP of business development. James was previously a co-founder and is current board member of SynDevRx, Inc., an oncology-focused biotech company and was a co-founder and VP corporate development of JAM Technologies, Inc. James brings 15 years business development and marketing experience to Ariana.

“The US pharma and biotech markets tend to be early technology adopters, and are searching for better data analytics tools to advance personalized medicine using all the new biomarker, genomic, proteomic and metabolomic data now being generated,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma. “Our KEM technology is the only proven approach that can simultaneously analyze all these variables and pull out patient responder sub-groups, optimize biomarker signatures and remove bias from clinical trials.”

James Shanahan believes Ariana offers something special and desperately needed by the pharmaceutical industry. “Companies spend tens of millions of dollars generating data. Now, it’s all about making sense of that data, and KEM is a real game-changer for the pharma and biotech industries. It identifies useful, complex biological relationships that statistics routinely miss.”

KEM – or Knowledge Extraction and Management – is an association rules-based (non-statistical) analytical technology that finds patient responder sub-populations and biomarker signatures that statistical methods are unable to detect. KEM optimizes clinical trial inclusion/exclusion criteria thereby lowering the number of patients needed to reach clinical endpoints and saving sponsors both time and cash.

About Ariana Pharma http://www.arianapharma.com

Ariana is a spin-out of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis. It is the only FDA-tested technology that can simultaneously analyze and optimize multi-parameter data, identify patient responders and clinical bias, and thereby reduce clinical drug development risk. Ariana is made up of an experienced inter-disciplinary team of PhD biologists, bio-statisticians, chemists and clinical experts. Ariana(R) was founded in 2003 and provides data analysis services to a large number of pharmaceutical, cosmetic and biotechnology companies. Ariana is headquartered In Paris, France and also has offices in Cambridge, Massachusetts, USA.

Mark Tidmarsh

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

mark@ala.com

Follow us on Twitter: https://twitter.com/ALA_Group

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES